Replimune Group (NASDAQ:REPL) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Replimune Group has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, reflecting negative sentiment about the company’s stock performance.
• The stock has seen significant downgrades in target prices, with analysts from Leerink Partners and Barclays both reducing their target prices to as low as $3.00.
• Replimune Group's latest earnings report showed a loss of ($0.95) per share, which missed analyst expectations by ($0.12), indicating ongoing financial struggles for the company.

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

A number of other research analysts have also recently commented on REPL. Leerink Partners reaffirmed a "market perform" rating and issued a $3.00 target price (down previously from $21.00) on shares of Replimune Group in a research report on Tuesday, July 22nd. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Replimune Group in a research note on Friday, September 19th. Barclays lowered Replimune Group from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $17.00 to $3.00 in a report on Wednesday, July 23rd. BMO Capital Markets lowered shares of Replimune Group from an "outperform" rating to an "underperform" rating and cut their target price for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Finally, Leerink Partnrs cut shares of Replimune Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 22nd. Two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, Replimune Group has a consensus rating of "Reduce" and a consensus target price of $6.50.

Replimune Group Price Performance

REPL traded down $0.14 on Tuesday, hitting $4.43. 2,501,020 shares of the company's stock were exchanged, compared to its average volume of 4,004,489. The firm has a 50-day moving average price of $5.12 and a 200-day moving average price of $7.39. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21. The stock has a market cap of $345.42 million, a price-to-earnings ratio of -1.37 and a beta of 0.42. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). As a group, equities analysts anticipate that Replimune Group will post -2.97 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In related news, CFO Emily Luisa Hill sold 9,154 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer owned 134,368 shares in the company, valued at $721,556.16. This represents a 6.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of REPL. BNP Paribas Financial Markets increased its stake in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after buying an additional 1,879 shares during the period. Deutsche Bank AG increased its position in Replimune Group by 0.4% during the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock worth $5,496,000 after purchasing an additional 2,140 shares during the period. Arizona State Retirement System grew its holdings in Replimune Group by 19.7% during the first quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock worth $151,000 after acquiring an additional 2,545 shares during the period. MetLife Investment Management LLC lifted its holdings in Replimune Group by 7.8% in the first quarter. MetLife Investment Management LLC now owns 40,598 shares of the company's stock valued at $396,000 after acquiring an additional 2,939 shares during the period. Finally, Corebridge Financial Inc. boosted its position in shares of Replimune Group by 11.0% during the 1st quarter. Corebridge Financial Inc. now owns 33,584 shares of the company's stock worth $327,000 after purchasing an additional 3,317 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.